These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1836 related articles for article (PubMed ID: 22246443)
1. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Friberg L; Rosenqvist M; Lip GY Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443 [TBL] [Abstract][Full Text] [Related]
2. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004 [TBL] [Abstract][Full Text] [Related]
3. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study. Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375 [TBL] [Abstract][Full Text] [Related]
4. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018 [TBL] [Abstract][Full Text] [Related]
5. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744 [TBL] [Abstract][Full Text] [Related]
6. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389 [TBL] [Abstract][Full Text] [Related]
7. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005 [TBL] [Abstract][Full Text] [Related]
8. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. Lip GY; Frison L; Halperin JL; Lane DA J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555 [TBL] [Abstract][Full Text] [Related]
9. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Friberg L; Benson L; Lip GY Eur Heart J; 2015 Feb; 36(5):297-306. PubMed ID: 24722803 [TBL] [Abstract][Full Text] [Related]
10. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Jover E; Roldán V; Gallego P; Hernández-Romero D; Valdés M; Vicente V; Lip GY; Marín F Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):627-33. PubMed ID: 22609214 [TBL] [Abstract][Full Text] [Related]
11. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231 [TBL] [Abstract][Full Text] [Related]
12. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. Poli D; Lip GY; Antonucci E; Grifoni E; Lane D J Cardiovasc Electrophysiol; 2011 Jan; 22(1):25-30. PubMed ID: 20653814 [TBL] [Abstract][Full Text] [Related]
13. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Olesen JB; Lip GY; Lane DA; Køber L; Hansen ML; Karasoy D; Hansen CM; Gislason GH; Torp-Pedersen C Am J Med; 2012 Aug; 125(8):826.e13-23. PubMed ID: 22579139 [TBL] [Abstract][Full Text] [Related]
14. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Lip GY; Banerjee A; Lagrenade I; Lane DA; Taillandier S; Fauchier L Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):941-8. PubMed ID: 22923275 [TBL] [Abstract][Full Text] [Related]
15. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Friberg L; Rosenqvist M; Lip GY Circulation; 2012 May; 125(19):2298-307. PubMed ID: 22514252 [TBL] [Abstract][Full Text] [Related]
16. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GY J Am Coll Cardiol; 2013 May; 61(20):2079-87. PubMed ID: 23524209 [TBL] [Abstract][Full Text] [Related]
17. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192 [TBL] [Abstract][Full Text] [Related]
18. Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation. Giralt-Steinhauer E; Cuadrado-Godia E; Ois A; Jiménez-Conde J; Rodríguez-Campello Á; Soriano C; Roquer J Eur J Neurol; 2013 Apr; 20(4):623-8. PubMed ID: 22834861 [TBL] [Abstract][Full Text] [Related]
19. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J; Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125 [TBL] [Abstract][Full Text] [Related]
20. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Olesen JB; Lip GY; Lindhardsen J; Lane DA; Ahlehoff O; Hansen ML; Raunsø J; Tolstrup JS; Hansen PR; Gislason GH; Torp-Pedersen C Thromb Haemost; 2011 Oct; 106(4):739-49. PubMed ID: 21789337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]